New Hope for Kids: Orthofix's Advanced Limb Lengthening Technology

ORLANDO, FL – May 06, 2026 – As leading pediatric orthopedic specialists gather for their annual meeting, Orthofix Medical Inc. is capturing the spotlight with new innovations aimed at transforming one of the most challenging areas of pediatric care: limb reconstruction. The Texas-based medical technology company is using the Pediatric Orthopedic Society of North America (POSNA) 2026 Annual Meeting to showcase a suite of advanced tools designed to provide less invasive and more precise treatment options for children and small stature patients with limb deformities.

At the heart of the announcement are the recently launched FITBONE™ Trochanteric Intramedullary Lengthening System, a novel internal implant, and significant enhancements to its OrthoNext™ digital planning software. Together, these advancements represent a significant step forward, offering surgeons greater flexibility and promising young patients a path to recovery with potentially less pain, fewer complications, and a better quality oflife.

Addressing a Critical Need in Pediatric Care

For children with significant limb length discrepancies or complex deformities, the journey to correction can be long and arduous. These conditions, whether congenital, post-traumatic, or developmental, can lead to debilitating issues, including gait abnormalities, chronic pain, and joint problems if left untreated. For decades, the standard of care often involved bulky external fixators—metal frames attached to the bone with pins or wires that protrude through the skin.

While effective, external fixation carries a heavy burden for patients, particularly children. The devices can be painful, carry a high risk of pin-site infections, and significantly impact mobility and daily activities. The visible nature of the frames can also lead to social and psychological challenges during a critical period of development.

The medical community has long sought better alternatives, driving a market shift toward internal lengthening devices. These fully implantable systems, controlled from outside the body, eliminate the need for external frames, dramatically reducing infection risk and patient discomfort. This shift is a key driver in the global limb lengthening market, which was valued at over $4 billion in 2023 and is projected to more than double to $8.31 billion by 2031. By offering a more patient-friendly approach, internal systems allow for faster rehabilitation and a quicker return to normal life.

A Closer Look at the Innovations

Orthofix's latest offerings are designed to push the boundaries of what's possible with internal lengthening. The FITBONE Trochanteric Lengthening System is an intramedullary nail—a rod inserted inside the bone—that can be gradually extended to lengthen the femur. Its key innovation lies in its design, which allows for a trochanteric entry, a surgical approach through the top of the femur bone. This provides a crucial alternative for patients whose anatomy is not suited for other entry points.

Critically for its target population, the system boasts the smallest proximal diameter of any intramedullary lengthening device currently on the market. This makes it a viable option for a broader range of pediatric patients aged 12 to 21, as well as small-statured adults who were previously difficult to treat with existing internal devices. Built on the FITBONE platform's two-decade clinical history, the device uses a reliable electromagnetic drive for consistent, controlled lengthening.

Complementing the advanced hardware is the newly enhanced OrthoNext 2.1 planning software. This powerful digital tool integrates with Orthofix's TrueLok Hexapod System (TL-HEX), a circular external fixator used for highly complex corrections. The software now provides a unified platform for surgeons to plan both internal and external fixation procedures with unprecedented precision.

New features in OrthoNext 2.1 include a strut event calendar to streamline surgical scheduling and, for the first time in this product segment, the use of artificial intelligence to automatically identify calibration markers on X-rays. This AI-powered function simplifies a crucial step in postoperative planning, saving time and reducing potential for error. Other enhancements, like independent second-ring movement and 3D ring modeling, give surgeons powerful tools to visualize and execute complex corrections more efficiently.

“Building on the success of our FITBONE limb-lengthening portfolio, the introduction of the FITBONE Trochanteric system marks an important milestone for Orthofix and the surgeons and patients we serve,” said Patrick Fisher, President of Global Biologics and Limb Reconstruction, in a statement. “This innovation enables surgeons to treat a broader spectrum of patients... In addition, the latest OrthoNext 2.1 planning software enhancements underscore our focus on delivering integrated digital and surgical tools that simplify deformity analysis and streamline correction planning.”

Navigating a Competitive and Growing Market

Orthofix is positioning these innovations within a dynamic and competitive landscape. The company's primary competitor in the internal lengthening space is NuVasive, whose Precice system is also a market leader and received expanded FDA clearance for pediatric use in 2023. The Precice system uses a magnetic mechanism for lengthening and offers small-diameter nails to treat younger patients.

Orthofix aims to differentiate itself through the specific technical advantages of its new system. The combination of a trochanteric entry option and the market's smallest proximal diameter gives surgeons a unique tool for specific patient anatomies that might not be ideal for other systems. Furthermore, the deep integration of its hardware with the sophisticated OrthoNext 2.1 software creates a comprehensive ecosystem for deformity correction. This strategy of bundling innovative implants with powerful digital planning tools is central to the company's effort to gain market share.

This strategic push is backed by strong performance. In the first quarter of 2026, Orthofix reported that its Global Limb Reconstruction division saw net sales grow by 10% compared to the prior year, indicating robust demand for its existing products. The company reaffirmed its full-year financial guidance, signaling confidence that new launches like the FITBONE Trochanteric system, which received FDA 510(k) clearance and began its U.S. commercial launch in March 2026, will be key contributors to its continued growth.

By focusing on the unmet needs of a vulnerable patient population and providing surgeons with more advanced and efficient tools, Orthofix is not just competing in a growing market but is actively working to redefine the standard of care in pediatric orthopedics. The integration of meticulously engineered implants with intelligent software represents a powerful synergy, promising a future where limb reconstruction is less of an ordeal and more of a precise, predictable path toward restored mobility for children.